Dr. Shlomo Nass has been appointed chairman of the board at InMode, a Nasdaq-listed medical technology company specializing in minimally invasive aesthetic and medical procedures. He succeeds former chairman Dr. Michael Anghel, who recently retired. InMode also promoted Moshik Itzkovich, previously senior vice president of finance, to chief financial officer, replacing Yair Malca, who stepped down earlier this month and will remain as a consultant during the transition.
CEO Moshe Mizrahy stated that Dr. Nass brings extensive experience in corporate governance, financial oversight, and regulatory matters, which will support the company’s strategic execution and shareholder-focused initiatives. Nass has decades of experience in corporate law, accounting, audit oversight, and governance advisory for both public and private companies—expertise increasingly critical for medtech firms in heavily regulated global healthcare markets.
Regarding the CFO transition, Mizrahy noted that Itzkovich’s experience working alongside Malca over the past several years positions him to maintain financial discipline and support long-term operational goals. The company emphasized continuity and operational stability, highlighting Itzkovich’s familiarity with InMode’s financial operations, capital structure, and strategic planning.
InMode develops and manufactures radiofrequency-based medical technologies for plastic surgery, dermatology, gynecology, ophthalmology, and related specialties, focusing on minimally invasive and non-invasive procedures. The leadership changes come as the company expands globally, balancing growth opportunities with increasing scrutiny on profitability, operational efficiency, and market expansion.
The board and finance appointments reflect the growing importance of governance and financial oversight for publicly traded medtech companies navigating reimbursement complexity, regulatory compliance, and international commercial expansion. InMode credited outgoing CFO Yair Malca with guiding the company through its transition into a public entity and establishing a strong financial foundation.
The company said the leadership changes are intended to support continued execution across product innovation, operational growth, and global market expansion as demand for minimally invasive medical procedures evolves worldwide.
Source: Read the original report | Published: May 20, 2026